Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Chemoradiotherapy in Nasopharyngeal Carcinoma
NCT04446663Phase 2Unknown
- Sponsor
- Foshan First People's Hospital
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of toripalimab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Foshan First People's Hospital. Primary endpoint: Adverse events at 2 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04446663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446663.